Drug Design in the context of the Cancer: Recent advance

Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries. Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018.

Acknowledging the current situation regarding covid-19 and cancer research, Drug Designing: Open Access Journal is coming up with a special issue titled: “Drug Design in the context of the Cancer: Recent advance” which has been edited by Dr. Gjumrakch Aliev.

Dr. Gjumrakch Aliev is the President and CEO of GALLY International Biomedical Research Consulting LLC, San Antonio, USA. He has a vast scope and experience as medical researcher on cancer.

We warmly and enthusiastically invite the eminent researchers to take part in this special issue to enhance recent advancements in cancer research.

We encourage submission of research articles, review articles, short communication, mini-review, case reports, editorial, etc. through email at drugdesign@eclinicalsci.org

The submission deadline is November 25^th, 2020.

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Journal is now accepting manuscripts for its upcoming issue Volume 9 Issue 4. Special Issue aims to publish manuscripts explaining drug synthesis, trails, production, action on viral molecules, chemical formulation, treatment reports etc.

Authors may submit original research article, review article, case studies, short commentary, systemic reviews, editorials etc. Mail us at drugdesign@eclinicalsci.org if interested and for queries.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org